![](https://www.lachmanconsultants.com/wp-content/uploads/2023/03/iStock-1351641405.jpg)
REMS Bill – Is It Really the Answer?
The Hill report (here) that “Sens. Maggie Hassan (D-N.H.) and Mike Braun (R-Ind.) on Wednesday reintroduced legislation intended to close a loophole that drug companies can exploit to block competition, including from lower-cost generic drugs.” The bill would permit FDA to approve a drug product for a generic immediately if all other approval requirements are […]